Nautilus Biotechnology v. SomaLogic: Declaratory Judgment Dismissed With Prejudice
Nautilus Biotechnology sought court confirmation that its Proteome Analysis Platform does not infringe US7842793, a patent held in connection with SomaLogic and Caltech. The parties jointly stipulated to dismiss the action with prejudice after 347 days, with each side bearing its own costs — ending Nautilus’s bid for a clean non-infringement declaration.
Proteomics patent standoff ends in stipulated dismissal with prejudice
On December 14, 2023, Nautilus Biotechnology, Inc. filed a declaratory judgment action in the Northern District of California (Case No. 5:23-cv-06440) seeking a court ruling that its Proteome Analysis Platform does not infringe US Patent No. 7,842,793. The defendants named were SomaLogic, Inc., the California Institute of Technology (Caltech), and Panther Merger Subsidiary II — entities with overlapping interests in the subject patent. Judge Beth Labson Freeman presided over the case.
The case closed on November 25, 2024, when the parties filed a joint stipulation of dismissal with prejudice. Crucially, defendants had asserted no counterclaims at any point. Under the stipulation, Nautilus’s declaratory judgment cause of action was extinguished, and each side agreed to bear its own attorneys’ fees and costs. A dismissal with prejudice bars Nautilus from re-filing the identical non-infringement claim — a meaningful constraint given the patent remains in force.
The 347-day duration and the absence of any counterclaims suggest the parties may have reached a commercial accommodation outside the public record, though the stipulation is silent on any licensing or business terms. The fact that Nautilus initiated the action — rather than waiting to be sued — is consistent with a defensive strategy common among emerging biotech platforms seeking IP certainty ahead of commercialisation. What drove the ultimate decision to dismiss, rather than pursue a merits ruling, remains unknown from the public record.
Filing to Dismissed with Prejudice in 347 days
347 days — resolved within one calendar year, faster than the median N.D. Cal. patent case
Dismissed with prejudice: what the stipulated exit means for both sides
Dismissal with prejudice bars re-filing the same DJ claim
A stipulated dismissal with prejudice under the Federal Rules operates as a final adjudication on the merits of the dismissed claim. Nautilus cannot return to federal court to seek the same declaratory judgment of non-infringement of US7842793. This is a stronger procedural closure than a without-prejudice dismissal, which would preserve the right to re-file. No counterclaims were pending, so no other claims remain.
Rule 41(a) — with prejudiceNautilus exits without a non-infringement declaration
Nautilus filed this action specifically to obtain judicial confirmation that its Proteome Analysis Platform is clear of US7842793. By agreeing to dismiss with prejudice, it walks away without that declaration. This forecloses the specific federal DJ route for this patent. Any future IP certainty on this patent would need to come through a different legal mechanism, a new cause of action on different grounds, or a private agreement — none of which are disclosed in the public record.
No DJ granted — platform risk unresolved publiclyUS7842793 survives unchallenged; no counterclaims were filed
SomaLogic, Caltech, and Panther Merger Subsidiary II never asserted counterclaims in this action, meaning they did not pursue infringement claims against Nautilus through this litigation. The patent exits the proceeding with its validity and enforceability legally undisturbed. The defendants’ decision not to assert counterclaims may reflect a strategic preference to preserve enforcement optionality rather than risk a merits ruling on infringement.
Patent enforceable — no validity rulingProteomics IP landscape: uncertainty persists for platform developers
US7842793 covers technology relevant to aptamer-based protein detection — a domain directly relevant to next-generation proteomics platforms. The absence of a merits ruling means the patent’s scope has not been judicially tested in this dispute. Competing platform developers and investors in the proteomics space should treat the patent as an active, unresolved risk. The case outcome is consistent with a negotiated resolution, though no licence terms are publicly disclosed.
Active patent risk — sector-wide relevanceFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Nautilus Biotechnology, Inc. | Company | Proteomics platform company — holder of DJ claim against US7842793Search in Eureka ↗ |
| Defendant | SomaLogic | Individual | SomaLogic, Caltech & Panther Merger Sub II — interests in US7842793 proteomics patentSearch in Eureka ↗ |
| Plaintiff counsel | Derek C. Walter | Attorney | Counsel for Nautilus Biotechnology, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Edward Robert Reines | Attorney | Counsel for Nautilus Biotechnology, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Weil Gotshal & Manages, LLP | Law Firm | Representing Nautilus Biotechnology, Inc.Search in Eureka ↗ |
| Defendant counsel | Sandra Linette Haberny | Attorney | Counsel for SomaLogicSearch in Eureka ↗ |
| Defendant law firm | Quinn Emanuel Urquhart & Sullivan, LLP | Law Firm | Representing SomaLogicSearch in Eureka ↗ |
| Presiding judge | Judge Beth Labson Freeman | Judge | California Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation is precise in its legal effect: only Nautilus’s declaratory judgment cause of action is dismissed — and it is dismissed with prejudice. The defendants’ explicit decision not to assert counterclaims, recorded in the stipulation’s recitals, means no infringement claim against Nautilus was ever put before the court. The phrase ‘each side shall bear its own costs and attorneys’ fees’ is a standard feature of negotiated exits and does not indicate which party holds the stronger underlying IP position. The court’s role here was confirmatory, not adjudicatory — it approved a party-negotiated resolution rather than deciding any substantive patent question.
US7842793 — Aptamer-Based Protein Detection and Proteome Analysis
US Patent No. 7,842,793 (application number US11/452699) relates to technology in the domain of aptamer-based affinity reagents used for protein detection and proteome-scale analysis. Aptamer technologies are a foundational component of several next-generation proteomics platforms, including SomaLogic’s SomaScan technology. The patent’s issuance and continued enforcement reflects the commercial significance of proprietary detection chemistries in a field where platform differentiation often turns on reagent specificity and multiplexing capability.
For competitors and new entrants in the proteomics space, US7842793 represents a potential blocking position over methods central to high-throughput protein quantification. The involvement of Caltech as a co-party suggests the patent may have academic origins with commercial licensing arrangements downstream. The fact that Nautilus — a well-capitalised proteomics startup — chose to proactively litigate rather than design around or license underscores the strategic importance of this patent to platform freedom of operation in the sector.
Should you run an FTO analysis against US7842793?
Any company developing aptamer-based protein detection, affinity-reagent proteomics, or multiplexed protein quantification platforms should treat US7842793 as a priority FTO target. The fact that a well-funded proteomics company sought judicial non-infringement clearance — and ultimately withdrew without obtaining it — signals that the patent’s claim scope is non-trivial and potentially broad enough to implicate competing platform architectures. R&D and product teams building in this space should not assume design freedom without a formal FTO assessment.
PatSnap Eureka’s FTO Search Agent enables IP and R&D teams to rapidly map the claim landscape of US7842793, identify prosecution history disclaimers, locate prior art that may narrow enforceable scope, and benchmark against the specific technical architecture of your platform. Given that no claim construction was issued in this case, Eureka’s analysis can help frame the key interpretive uncertainties before you engage outside counsel — saving time and reducing the cost of a full written opinion.
Run a freedom-to-operate analysis on US7842793B2 to assess your product’s exposure
Run FTO in Eureka →Similar declaratory judgment cases in proteomics and biotech IP
Explore related DJ non-infringement actions filed in the Northern District of California involving proteomics, aptamer, and affinity-reagent platform patents.
What this case signals for the proteomics and biotech IP landscape
The Nautilus–SomaLogic dispute illustrates the growing use of declaratory judgment actions as a proactive IP clearance tool in competitive proteomics.
DJ actions are becoming a first-mover tool in biotech platform competition
Rather than waiting to be sued, Nautilus proactively sought judicial clearance for its platform — a pattern increasingly seen among emerging biotech companies navigating dense patent landscapes prior to commercialisation. This case reinforces that filing a DJ action does not guarantee a merits ruling; parties may resolve the underlying dispute through channels that never surface in the public record.
Absence of counterclaims is a meaningful strategic signal
SomaLogic and co-defendants chose not to assert infringement counterclaims despite having the procedural opportunity to do so. This suggests either that defendants did not view their infringement position as strong enough to pursue in this forum, or that a commercial arrangement rendered litigation unnecessary. Either reading is relevant for competitors assessing the practical enforceability of US7842793.
Nautilus v SomaLogic — key questions answered
The case was dismissed with prejudice by joint stipulation on November 25, 2024. Nautilus had sought a declaratory judgment of non-infringement of US7842793. No counterclaims were asserted by defendants. Each party agreed to bear its own costs and attorneys’ fees. The dismissal with prejudice bars Nautilus from re-filing the same DJ claim in federal court.
US7842793 relates to aptamer-based protein detection technology relevant to proteome analysis platforms. Nautilus filed a declaratory judgment action seeking confirmation that its Proteome Analysis Platform does not infringe the patent. This type of proactive filing is consistent with a strategy to secure IP clearance ahead of commercial launch, rather than waiting to face an infringement suit.
Caltech’s involvement as a defendant suggests it holds an ownership or co-ownership interest in US7842793, consistent with a university-origin patent licensed or assigned downstream to SomaLogic. Panther Merger Subsidiary II appears to be a corporate entity connected to SomaLogic’s corporate structure. All three entities were named to ensure complete resolution of any party with rights in the patent.
No. A dismissal with prejudice of a declaratory judgment action does not constitute a finding of infringement. It means only that Nautilus’s specific DJ claim cannot be re-filed. The court made no ruling on infringement or validity. The underlying merits of the non-infringement question were never adjudicated in this proceeding.
Defendants — SomaLogic, Caltech, and Panther — did not assert counterclaims for infringement against Nautilus during the litigation. This is strategically notable: it means no infringement claim was put before the court. It may suggest defendants did not have a strong infringement position in this forum, or that a commercial resolution made formal counterclaims unnecessary. The public record does not disclose the reason.
PatSnap Eureka searches patents and litigation data to answer instantly.